SunBio, Inc. develops biosimilars, biopharmaceuticals, medical devices, and cosmetic products based on proprietary technologies comprised of site-directed pegylation of proteins, cell engineering technology, and novel pegylation technologies. The company was founded on June 10, 1997 and is headquartered in Gunpo-si, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company